efaroxan has been researched along with 4-chloro-2-(2-imidazolin-2-ylamino)isoindoline in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agbaba, D; Filipic, S; Nikolic, K | 1 |
| Agbaba, D; Azzali, E; Costantino, G; Glisic, S; Laurila, JM; Nikolic, K; Perovic, V; Pieroni, M; Radi, M; Scheinin, M; Srdic-Rajic, T; Tassini, S; Veljkovic, N; Vucicevic, J | 1 |
2 other study(ies) available for efaroxan and 4-chloro-2-(2-imidazolin-2-ylamino)isoindoline
| Article | Year |
|---|---|
QSAR study of imidazoline antihypertensive drugs.
Topics: Antihypertensive Agents; Binding Sites; Imidazoline Receptors; Imidazolines; Ligands; Models, Molecular; Molecular Structure; Quantitative Structure-Activity Relationship | 2008 |
A combined ligand- and structure-based approach for the identification of rilmenidine-derived compounds which synergize the antitumor effects of doxorubicin.
Topics: Adrenergic alpha-Agonists; Antibiotics, Antineoplastic; Apoptosis; Doxorubicin; Drug Synergism; Humans; K562 Cells; Ligands; Molecular Structure; Oxazoles; Receptors, Adrenergic, alpha-2; Rilmenidine | 2016 |